ASCT and MT affected both PFS and OS in the patients achieving a partial response prior to ASCT. (A) The median PFS ± standard deviation of the four arms (ASCT/MT, ASCT/non-MT, non-ASCT/MT, non-ASCT/non-MT) was 42±11.52, 17±5.477, 26±4.942 and 12±7.73, respectively. (B) The 3-year OS rate of the four arms (ASCT/MT, ASCT/non-MT, non-ASCT/MT, non-ASCT/non-MT) (ASCT/MT, ASCT/non-MT, non-ASCT/MT, non-ASCT/non-MT) was 100, 40, 66 and 35%, respectively. PFS, progression-free survival; OS, overall survival; ASCT, autologous hematopoietic stem cell transplantation; MT, maintenance therapy.